COVID-19疫苗接种后报告的神经系统事件:疫苗不良事件报告系统分析
本研究基于美国疫苗不良事件报告系统(VAERS)2021年1月1日至2021年6月14日的数据,分析mRNA疫苗(辉瑞、莫德纳)与腺病毒载体疫苗(杨森)接种后神经系统事件报告率。研究期内共接种306,907,697剂COVID疫苗,314,610人(0.1%)报告任何不良事件,105,214人(0.03%)报告神经系统不良事件,接种至报告的中位时间为1天(IQR 0-3)。杨森疫苗接种后神经系统不良事件报告率显著高于辉瑞或莫德纳(分别为0.15% vs 0.03% vs 0.03%,p<0.0001);杨森疫苗接种后吉兰-巴雷综合征、脑静脉血栓形成和癫痫的观察值与预期值之比≥1.5倍于背景发生率;但急性SARS-CoV-2感染后神经系统事件发生率最高达COVID疫苗接种后的617倍。
要点
- 研究期内共接种306,907,697剂COVID疫苗,105,214人(0.03%)报告神经系统不良事件,中位报告时间为接种后1天(IQR 0-3)。
- 杨森疫苗接种后神经系统不良事件报告率为0.15%,高于辉瑞的0.03%和莫德纳的0.03%(p<0.0001)。
- 急性SARS-CoV-2感染后神经系统事件发生率最高达COVID疫苗接种后的617倍。
核心结论
- COVID疫苗接种后严重神经系统事件报告罕见;杨森疫苗接种后吉兰-巴雷综合征、脑静脉血栓形成和癫痫发生率可能高于背景水平;但急性SARS-CoV-2感染后神经系统并发症发生率最高达COVID疫苗接种后的617倍。
研究设计与样本
- 研究使用美国疫苗不良事件报告系统(VAERS)2021年1月1日至2021年6月14日的公开数据。
- 对接种后42天内报告的所有自由文本症状进行人工审阅,并归入36个神经系统诊断类别。
- 将接种后神经系统事件报告率在疫苗类型间比较,并与美国年龄匹配的背景发生率及COVID后神经系统事件发生率比较。
主要发现
- 研究期内共接种306,907,697剂COVID疫苗,314,610人(0.1%)报告任何不良事件,105,214人(0.03%)报告神经系统不良事件,中位报告时间为接种后1天(IQR 0-3)。
- 吉兰-巴雷综合征和脑静脉血栓形成发生率低于每1,000,000剂1例。
- 杨森疫苗接种后神经系统不良事件报告数显著多于辉瑞或莫德纳(分别为0.15% vs 0.03% vs 0.03%,p<0.0001)。
- 杨森疫苗接种后吉兰-巴雷综合征、脑静脉血栓形成和癫痫的观察值与预期值之比≥1.5倍于背景发生率。
- 急性SARS-CoV-2感染后神经系统事件发生率最高达COVID疫苗接种后的617倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S. METHODS: We used publicly available data from the U.S. Vaccine Adverse Event Reporting System (VAERS) collected between January 1, 2021 and June 14, 2021. All free text symptoms that were reported within 42 days of vaccine administration were manually reviewed and grouped into 36 individual neurological diagnostic categories. Post-vaccination neurological event rates were compared between vaccine types and to age-matched baseline incidence rates in the U.S. and rates of neurological events following COVID. RESULTS: Of 306,907,697 COVID vaccine doses administered during the study timeframe, 314,610 (0.1%) people reported any adverse event and 105,214 (0.03%) reported neurological adverse events in a median of 1 day (IQR0-3) from inoculation. Guillain-Barre Syndrome (GBS), and cerebral venous thrombosis (CVT) occurred in fewer than 1 per 1,000,000 doses. Significantly more neurological adverse events were reported following Janssen (Ad26.COV2.S) vaccination compared to either Pfizer-BioNtech (BNT162b2) or Moderna (mRNA-1,273; 0.15% vs 0.03% vs 0.03% of doses, respectively, p < 0.0001). The observed-to-expected ratios for GBS, CVT and seizure following Janssen vaccination were ≥1.5-fold higher than background rates. However, the rate of neurological events after acute SARS-CoV-2 infection was up to 617-fold higher than after COVID vaccination. INTERPRETATION: Reports of serious neurological events following COVID vaccination are rare. GBS, CVT and seizure may occur at higher than background rates following Janssen vaccination. Despite this, rates of neurological complications following acute SARS-CoV-2 infection are up to 617-fold higher than after COVID vaccination. ANN NEUROL 2022;91:756-771.
引用
- Frontera JA, Tamborska AA, Doheim MF, et al. Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Ann Neurol. 2022. PMID: 35233819. doi:10.1002/ana.26339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。